Brokerages expect Neos Therapeutics Inc (NASDAQ:NEOS) to post ($0.24) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Neos Therapeutics’ earnings. Neos Therapeutics reported earnings per share of ($0.23) during the same quarter last year, which would suggest a negative year over year growth rate of 4.3%. The business is expected to announce its next quarterly earnings results on Thursday, March 12th.
On average, analysts expect that Neos Therapeutics will report full-year earnings of ($0.31) per share for the current year, with EPS estimates ranging from ($0.32) to ($0.30). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.20) per share, with EPS estimates ranging from ($0.24) to ($0.15). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that follow Neos Therapeutics.
Neos Therapeutics (NASDAQ:NEOS) last released its earnings results on Friday, November 8th. The company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.06. The company had revenue of $17.54 million during the quarter. Neos Therapeutics had a negative return on equity of 2,087.24% and a negative net margin of 35.77%.
Several hedge funds and other institutional investors have recently made changes to their positions in NEOS. Alambic Investment Management L.P. lifted its position in Neos Therapeutics by 1,710.7% during the second quarter. Alambic Investment Management L.P. now owns 219,090 shares of the company’s stock valued at $283,000 after purchasing an additional 206,990 shares during the last quarter. Weiss Asset Management LP bought a new position in Neos Therapeutics during the second quarter valued at $36,000. Acadian Asset Management LLC bought a new position in Neos Therapeutics during the second quarter valued at $40,000. Paloma Partners Management Co bought a new position in Neos Therapeutics during the second quarter valued at $275,000. Finally, Jane Street Group LLC lifted its position in Neos Therapeutics by 332.1% during the second quarter. Jane Street Group LLC now owns 165,503 shares of the company’s stock valued at $213,000 after purchasing an additional 127,202 shares during the last quarter. 45.90% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:NEOS traded down $0.02 during midday trading on Friday, reaching $1.54. The company had a trading volume of 82,200 shares, compared to its average volume of 147,686. The company has a quick ratio of 0.91, a current ratio of 1.11 and a debt-to-equity ratio of 41.70. The business’s 50 day moving average price is $1.48 and its 200 day moving average price is $1.60. Neos Therapeutics has a 1-year low of $1.13 and a 1-year high of $3.62. The stock has a market cap of $77.58 million, a PE ratio of -0.96 and a beta of 0.93.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
See Also: Support Level
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.